Spotlight on Cardiovascular VC Funding In 1st Half 2006
Executive Summary
Atrial fibrillation is the hottest sector among five highly dynamic areas within cardiovascular technology, according to an analysis by cvPipeline.
You may also be interested in...
Tapping the Potential of Atrial Fibrillation Devices
A solid foundation has been laid in the field of devices for atrial fibrillation; clinical trials have underscored the efficacy of cardiac ablation devices compared to drugs, reimbursement is in place for both surgical and catheter-based ablation procedures, and large companies have invested heavily in the technologies, validating the entire field. Early devices on the market are bringing in some revenues for their developers, but much remains to be done before atrial fibrillation becomes the multi-billion market everyone talks about. The biggest challenge that lies ahead: clinical trials, for today, all ablation devices are used off-label for atrial fibrillation.
Proteus Biomedical Inc.
Proteus Biomedical Inc. is developing a suite of proprietary MEMS-based technologies for congestive heart failure. It is staking its first claim in the fast-growing cardiac resynchronization therapy market.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.